To the Editor:With the widespread application of immune checkpoint inhibitors(ICIs)in clinical practice,acquired resistance(AR)to programmed death-1(PD-1)/programmed death ligand 1(PD-L1)axis inhibitors in advanced no...To the Editor:With the widespread application of immune checkpoint inhibitors(ICIs)in clinical practice,acquired resistance(AR)to programmed death-1(PD-1)/programmed death ligand 1(PD-L1)axis inhibitors in advanced nonsmall cell lung cancer(NSCLC)develops and limits the durability of immunotherapy.AR is a clinical condition in which a patient initially responds to ICIs but relapses and progresses after a period of time.The rates of AR have not been routinely reported in lung cancer but typically range from 12.9%to 64%.[1]However,studies on subsequent management strategies and the mechanism of AR to PD-1/PD-L1 axis inhibitors in lung cancer are limited.The main exploratory strategies are immunotherapy rechallenge and the combination of ICIs with other therapies,including local therapy,chemotherapy,antiangiogenetic treatment,and cytotoxic T lymphocyte antigen 4(CTLA-4)inhibitors.[2]The purpose of this study was to characterize the clinical patterns of AR and compare different subsequent therapies and outcomes in NSCLC patients after AR to PD-1/PD-L1 inhibitors.Moreover,we explored the underlying mechanism of AR by analyzing the alterations in next-generation sequencing(NGS)data before and after AR.展开更多
基金National Natural Science Foundation of China(No.82173097 to Z.W.)National Key Research&Development Program of China(Nos.2022YFC2505000 and 2022YFC2505002 to H.L.)
文摘To the Editor:With the widespread application of immune checkpoint inhibitors(ICIs)in clinical practice,acquired resistance(AR)to programmed death-1(PD-1)/programmed death ligand 1(PD-L1)axis inhibitors in advanced nonsmall cell lung cancer(NSCLC)develops and limits the durability of immunotherapy.AR is a clinical condition in which a patient initially responds to ICIs but relapses and progresses after a period of time.The rates of AR have not been routinely reported in lung cancer but typically range from 12.9%to 64%.[1]However,studies on subsequent management strategies and the mechanism of AR to PD-1/PD-L1 axis inhibitors in lung cancer are limited.The main exploratory strategies are immunotherapy rechallenge and the combination of ICIs with other therapies,including local therapy,chemotherapy,antiangiogenetic treatment,and cytotoxic T lymphocyte antigen 4(CTLA-4)inhibitors.[2]The purpose of this study was to characterize the clinical patterns of AR and compare different subsequent therapies and outcomes in NSCLC patients after AR to PD-1/PD-L1 inhibitors.Moreover,we explored the underlying mechanism of AR by analyzing the alterations in next-generation sequencing(NGS)data before and after AR.
